drugset / Trial / NCT01877265

A Study of LY2605541 in Healthy Participants

NCT01877265

Phase 1 Completed 18 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

This study looks at the amount of LY2605541 in the body after it is injected under the skin. The study has 3 periods, each lasting 10 days. Each participant will receive one injection in each period. At least 14 days will pass between each injection.

Timeline

Start
2013-06
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Peglispro Protein / enzyme biologic 0.5 iu/kg Subcutaneous

Indications

No indication recorded.